SBRT and Nelfinavir 
Protocol Chair:  Phuoc Tran, MD  
J12137 (NA_00069585) - May 19, 2020 
 
 
1 
 Single-Arm Phase II Study of Stere otactic Body Radiation Therap y Concurrent with 
Nelfinavir for Oligometastases 
 
Protocol Number  J12137 (NA_00069585) 
IND Number    E x e m p t  
 
Principal Investigator  Phuoc tran, MD, M.D. 
Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University 
Weinberg Building 
401 N. Broadway, Suite 1440 Baltimore, MD 21231 Phone:  410-614-3880 Fax:  410-502-1419 
Email: tranp@jhmi.edu   
 
Co-Investigators  Russell Hales, M.D. 
Lawrence Kleinberg, M.D. Danny Song, M.D. Michael Lim, M.D. Fariba Asrari, M.D. 
Shirl DiPasquale, RN 
 
Statistician Hao Wang  
 
Research Managers: Dana Kaplin 
Terry Caldwell 
 
     
            
 
SBRT and Nelfinavir 
Protocol Chair:  Phuoc Tran, MD  
J12137 (NA_00069585) - May 19, 2020 
 
 
2 
 Table of Contents 
 
SCHEMA ........................................................ ............................................................... ............................................... 4  
1. PROTOCOL SYNOPSIS ............................................. ............................................................... ...................... 5  
2. ABBREVIATIONS AND DEFINITIONS OF TERMS ........................ .......................................................... 6  
3. OBJECTIVES .................................................... ............................................................... ................................. 7  
3.1  PRIMARY OBJECTIVE  .............................................................. ............................................................... ....... 7 
3.2  SECONDARY OBJECTIVES  .............................................................. ............................................................... . 7 
4. BACKGROUND .................................................... ............................................................... ............................. 7  
4.1  OLIGOMETASTATIC DISEASE ............................................................... .......................................................... 7  
4.2  STEREOTACTIC BODY RADIATION THERAPY (SBRT) ........................................................ ........................... 8  
4.3  TUMOR HYPOXIA  .............................................................. ............................................................... ............. 8 
4.4  NELFINAVIR  .............................................................. ............................................................... ..................... 8  
4.5  RATIONALE FOR USE IN PULMONARY METASTASIS  .............................................................. ........................ 9  
4.6  RATIONALE FOR USE IN LIVER METASTASIS  .............................................................. ................................. 10  
4.7  CONCURRENT SBRT  AND NELFINAVIR  .............................................................. ......................................... 11  
5. PARTICIPANT SELECTION AND  ENROLLMENT PROCEDURES ............... ..................................... 12  
5.1  INCLUSION CRITERIA  .............................................................. ............................................................... ..... 13 
5.2  EXCLUSION CRITERIA  .............................................................. ............................................................... .... 13 
6. TREATMENT PLAN ................................................ ............................................................... ....................... 14  
6.1  DIAGNOSTIC PROCEDURES  .............................................................. ............................................................ 14  
6.2  THERAPEUTIC PROCEDURES  .............................................................. ......................................................... 14  
6.3  FOLLOW -UP PROCEDURES  .............................................................. ............................................................ 16  
6.4  DURATION OF THERAPY  .............................................................. ............................................................... . 16 
6.5  DURATION OF FOLLOW -UP .............................................................. ........................................................... 17  
6.6  CRITERIA FOR PATIENT REMOVAL  .............................................................. ................................................ 17  
6.7  ALTERNATIVES  .............................................................. ............................................................... .............. 17  
6.8  COSTS  .............................................................. ............................................................... ............................ 17  
6.9  COMPENSATION  .............................................................. ............................................................... ............. 17  
6.10 WITHDRAWAL FROM STUDY  .............................................................. ......................................................... 18  
7. INVESTIGATIONAL AGENT/DEVICE/PROCEDURE INFORMATION ............ ................................. 18  
7.1  INVESTIGATIONAL AGENT  .............................................................. ............................................................ 18  
7.2  AVAILABILITY  .............................................................. ............................................................... ............... 18  
7.3  AGENT ACCOUNTABILITY  .............................................................. ............................................................. 1 8 
8. DOSING DELAYS/DOSE MODIFICATIONS .............................. .............................................................. 18 
9. CORRELATIVE/SPECI AL STUDIES ................................... ............................................................... ........ 18 
9.1  ASSESSMENT OF PHOSPHO -AKT .............................................................. .................................................... 18  
10. STUDY CALENDAR ................................................ ............................................................... ....................... 19  
11. MEASUREMENT OF EFFECT.......................................... ............................................................... ............ 21 
11.1 ANTITUMOR EFFECT -SOLID TUMORS ............................................................... ........................................... 21  
11.2 DEFINITIONS  .............................................................. ............................................................... .................. 21  
11.3 DISEASE PARAMETERS  .............................................................. ............................................................... ... 21 
11.4 METHODS FOR EVALUATION OF MEASURABLE DISEASE  .............................................................. .............. 22  
11.5 RESPONSE CRITERIA (VIA RECIST  1.1) .......................................................... ............................................ 22  
SBRT and Nelfinavir 
Protocol Chair:  Phuoc Tran, MD  
J12137 (NA_00069585) - May 19, 2020 
 
 
3 
 12. ADVERSE EVENT REPORTING REQUIREMENTS .......................... ..................................................... 23  
12.1 GENERAL  .............................................................. ............................................................... ....................... 23  
12.2 DEFINITIONS  .............................................................. ............................................................... .................. 24  
12.3 POTENTIAL ADVERSE EVENTS  .............................................................. ...................................................... 25  
12.4 STEREOTACTIC BODY RADIATION TREATMENT  .............................................................. ............................ 25  
12.5 NELFINAVIR  .............................................................. ............................................................... ................... 26  
12.6 FIDUCIAL IMPLANTATION  .............................................................. ............................................................. 2 7 
12.7 REPORTING PROCEDURES  .............................................................. ............................................................. 2 7 
13. DATA AND SAFETY MONITORING PLAN ............................... ...............................................................  2 8 
14. REGULATORY CONSIDERATIONS ..................................... ............................................................... ...... 28 
14.1 PROTOCOL REVIEW AND AMENDMENTS  .............................................................. ....................................... 28  
14.2 INFORMED CONSENT  .............................................................. ............................................................... ...... 28 
14.3 ETHICS AND GCP ........................................................... ............................................................... .............. 29  
15. STATISTICAL CONSIDERATIONS .................................... ............................................................... ......... 29 
15.1 ENDPOINTS  .............................................................. ............................................................... .................... 29  
15.2 SAMPLE SIZE/ACCRUAL RATE .............................................................. ...................................................... 29  
15.3 SAFETY RUN-IN PHASE  .............................................................. ............................................................... .. 30 
15.4 EARLY STOPPING GUIDELINES : ............................................................. ...................................................... 30  
15.5 ANALYSIS OF PRIMARY OBJECTIVE  .............................................................. .............................................. 31  
15.6 ANALYSIS OF SECONDARY OBJECTIVES  .............................................................. ........................................ 31  
15.7 EVALUATION OF TOXICITY  .............................................................. ........................................................... 31  
15.8 EVALUATION OF RESPONSE  .............................................................. .......................................................... 32  
REFERENCES: ................................................... ............................................................... ....................................... 33  
APPENDIX  I: BRIEF PAIN INVENTORY FORM .............................................................. ........................................... 37  
APPENDIX  II: SKCCC  DSMP .......................................................... ............................................................... ...... 39 
APPENDIX  III: PERFORMANCE STATUS CRITERIA  .............................................................. ................................... 40  
 
SBRT and Nelfinavir 
Protocol Chair:  Phuoc Tran, MD  
J12137 (NA_00069585) - May 19, 2020 
 
 
4 
 SCHEMA 
 
Radiation Oncology Consultation 
 
 
 
Research Participant Informed C onsent and Privacy Authorization  Form 
 
 
 
Eligibility Evaluation & Subsequent Enrollment 
  
 
Pre-Study Requirements* 
{ie. Coagulation Profile, Assay , CT or MRI, PET-CT (optional), etc.} 
 
 
 
Cycle #1 of Nelfinavir 
(1250mg BID/7 days) 
 
  
Stereotactic Body Radiation Therapy 
  
 
Cycle #2 of Nelfinavir 
(1250mg BID/7 days) 
 
  
Follow-Up Schedule 
  
 
 
 
  
 
  
 
  
 
 
*Pre-Study Requirements are specific to each patient 
* If scheduling or safety prevents  all lesions from being irrad iated within one day, participa nts will complete Cycle #2 of 
Nelfinavir then undergo a minimum of 7 days “clear out”. Follow ing this break participants will repeat Cycle #1 of Nelfinavir 
then receive radiation to the r emaining lesions f ollowed by a r epeat Cycle #2 of Nelfinavir. This process may not exceed three  
“rounds” of treatment (NFV1, SBRT , NFV2) and may include repeat  imaging and/or blood work. 
SBRT and Nelfinavir 
Protocol Chair:  Phuoc Tran, MD  
J12137 (NA_00069585) - May 19, 2020 
 
 
5 
 1. PROTOCOL SYNOPSIS 
TITLE Single-Arm Phase II Study of  Stereotactic Body Radiation 
Therapy Concurrent with Nelfi navir for Oligometastases 
STUDY PHASE Phase II 
INDICATION Patients presenting w ith oligometastatic disease, wh ere 
metastases are limited in number and location. 
PRIMARY OBJECTVES  To determine the 6-month  freedom from local 
progression rate of the radiose nsitizer Nelfinavir used 
concurrently with 15 Gy of stereotactic body radiation therapy (SBRT) de livered in 1 fraction (per 
lesion) in patients with o ligometastatic disease 
SECONDARY OBJECTIVES  To assess the toxicity of the  radiosensitizer Nelfinavir 
used concurrently with 1 5 Gy of stereotactic body 
radiation therapy (SBRT) de livered in 1 fraction(per 
lesion) in patients with o ligometastatic disease 
 To determine local control at 6 months after SBRT 
delivered to a dose of 15 Gy i n 1 fraction (per lesion) 
combined with Nelfinavir in patients with oligometastatic disease  
 To assess long-term clinical  outcomes of this patient 
population after completi on of SBRT in combination 
with Nelfinavir 
 To assess quality of life following completion of 
SBRT in combination with Nelfinavir  
 To determine the corre lation between phospho-Akt 
levels and lesion response rate 
HYPOTHESES Concurrent SBRT and Nelfinavir will achieve greater than  
70% freedom from local  progression  6 months.  
STUDY DESIGN Patients with met astatic lesions of the lung, live r, or bone 
will be candidates for treatmen t. Within three weeks of the 
initial treatment planning, a  15 Gy dose (per lesion) of SBRT 
will be administered.  Prior to SBRT, patients will initiate Nelfinavir oral ther apy twice daily for 7 days.  Once SBRT is 
completed, the patient will repeat the same Nelfinavir therapy for an additional 7 da ys for a total of 14 days of 
treatment. 
SAMPLE SIZE BY TREATMENT GROUP 42 patients total   
SUMMARY OF SUBJECT 
ELIGIBILITY CRITERIA 1. Metastasis at one or more of  the following sites: bone, 
liver, and/or lung. No more than 5 lesions will be treated. 
2. Tumor(s) to be treated is( are)  ≤ 5.0 cm or ≤250 cm3. 
3. Age > 18 years. 
4. ECOG perfomance status ≤ 2. 5. Histologic confirmation of malignancy (primary or metastatic tumor). 
SBRT and Nelfinavir 
Protocol Chair:  Phuoc Tran, MD  
J12137 (NA_00069585) - May 19, 2020 
 
 
6 
 INVESTIGATIONAL 
PRODUCTS DOSAGE AND ADMINISTRATION Commercially available Nel finavir (1250 mg) will be 
administered orally t wice daily for 14 days. 
CONTROL GROUP N/A 
PROCEDURES 1. Physical exam 
2. Blood draw 4. CT or MRI of Involved Site 5. PET-CT (all are optional) 6. SBRT + oral Nelfinavir administration 
 
2. ABBREVIATIONS AND DEFINITIONS OF TERMS 
Abbreviation Definition 
ADL Activities of daily living 
AE Adverse event 
BID Twice daily 
BSA Body surface area 
CBC Complete blood count 
CI Confidence interval 
CMAX Maximum concentration of drug 
CNS Central nervous system 
CRF Case report/Record form 
CR Complete response 
CTCAE Common Terminology Crite ria for Adverse Events 
DLT Dose Limiting Toxicity 
DSMB Data Safety Monitoring Board 
ECG Electrocardiogram 
GI Gastrointestinal 
Hgb Hemoglobin 
HIV Human Immunodeficiency Virus 
HPF High-power field  
HTN Hypertensions 
IRB Institutional Review Board 
IV Intravenous 
LLN Lower limit of normal  
MTD Maximum tolerated dose 
OS Overall survival  
PLT Platelet 
PD Progressive diseased 
PFS Progression free survival  
PR Partial response 
QD Once daily 
RECIST Response evaluation c riteria in solid tumors 
RR Response rate 
SAE Serious adverse event 
SBRT and Nelfinavir 
Protocol Chair:  Phuoc Tran, MD  
J12137 (NA_00069585) - May 19, 2020 
 
 
7 
 Abbreviation Definition 
SBRT Stereotactic body radiation therapy 
SD Stable disease 
TTP Time to progression 
ULN Upper limit of normal 
UNK Unknown 
WBC White blood cell 
WHO World Health Organization 
 
3. OBJECTIVES 
3.1 Primary Objective 
T o  d e t e r m i n e  t h e  6 - m o n t h  f r e e d o m  f r o m  l o c a l  p r o g r e s s i o n  r a t e  o f  the radiosensitizer 
Nelfinavir used concurrently with 15 Gy of stereotactic body ra diation therapy (SBRT) 
delivered in 1 fraction (per les ion) in patients with oligometa static disease. 
3.2 Secondary Objectives 
To assess the toxicity of the radiosensitizer Nelfinavir used c oncurrently with 15 Gy of 
stereotactic body radiation therapy (SBRT) delivered in 1 fract ion (per lesion) in patients 
with oligometastatic disease.  T o  d e t e r m i n e  l o c a l  c o n t r o l  a t  6  m o n t h s  a f t e r  S B R T  d e l i v e r e d  t o  a dose of 15 Gy in 1 
fraction (per lesion) combined w ith Nelfinavir patients with ol igometastatic disease. 
 
To assess long-term clinical out comes of this patient populatio n after completion of SBRT 
in combination with Nelfinavir.  To assess quality of life follo wing completion of SBRT in combi nation with Nelfinavir. 
 To determine the correlation be tween Phospho-Akt levels and les ion response rate. 
4. BACKGROUND 
4.1 Oligometastatic Disease 
Cancer is the second leading cause of death in the United State s, chiefly from an inability 
to control metastatic disease. S ystemic therapy alone is not cu rative for patients with most 
metastatic solid tumors.(1) The metastatic capacity of cancers behaves along a spectrum of 
disease progression, such that som e tumors have spread widely b efore clinical detectability 
and others never metastasize. Contained within this spectrum, i s an oligometastatic state 
where metastases are limited in number and location. The presen ce of an oligometastatic 
state was originally proposed by Hellman who suggested that the se oligometastatic patients 
would benefit from effective local therapy in addition to syste mic therapy.(1) In agreement 
with this hypothesis, surgery and chemotherapy for isolated pul monary metastases can 
result in long term disease-free periods. (2) Additionally, som e 25% of patients following 
SBRT and Nelfinavir 
Protocol Chair:  Phuoc Tran, MD  
J12137 (NA_00069585) - May 19, 2020 
 
 
8 
 resection and chemotherapy for colorectal cancer and isolated l iver metastases can 
similarly have long-term diseas e free survival.(3)(4)(5) 
 The treatment of metastases depends on multiple factors includi ng 1) the location of the 
primary tumor, 2) the presence or absence of other metastatic f oci, 3) the size, number and 
location of metastases, 4) the effectiveness of various forms o f therapy (such as surgery, 
radiation and chemotherapy), and 5) patient’s functional status . Extracranial metastatic 
tumors most often referred for l ocal therapy in the form of res ection include colon cancer, 
sarcomas, germ cell tumors, and melanoma metastatic to the lung . For the more common 
primary tumors such as those of breast and lung, metastases are  rarely referred for resection 
as chemotherapy (or hormonal manipulation) is generally conside red to be the primary 
mode of treatment. 
4.2 Stereotactic Body Radiation Therapy (SBRT) 
Conventional moderate dose radiation for metastatic disease is given primarily for 
palliation. Recent advancements in radiation delivery now make it possible to image and 
treat precisely within any ana tomical region of the body.(6, 7)  As a result, the capacity to 
deliver tumor killing radiation doses in a single or few (1-5) outpatient radiation treatments 
is now possible.(8-12) In addition, by minimizing the irradiati on of surrounding healthy 
tissue, it should also be possible to decrease the rate of comp lications. Intracranial 
stereotactic body radiation ther apy (SBRT) has been shown to be  a highly effective 
treatment for brain metastases.(13) This suggests that selectiv e small extracranial tumors 
(either primary or metastatic tu mors) may be effectively contro lled by similar focal high-
dose SBRT. There is an increasing experience with extracranial SBRT as effective local 
therapy for metastatic lesions. Local control in excess of 75% has been reported for 
metastatic tumors of the spine, lung and liver, which is signif icantly higher than standard 
conventional moderate dose radiation.(9, 11, 12, 14)(15) Toxici t y  h a s  b e e n  m i n i m a l  in  
multiple U.S., European and Japanese trials of extracranial ste reotactic radiotherapy to the 
lung, liver, spine, pelvis and abdomen despite the use of very high biological equivalent 
doses for patients with both orga n confined and metastatic canc er.  
4.3 Tumor Hypoxia 
Another factor potentially limiting the efficacy of SBRT or hyp ofractationated regimens is 
intratumoral hypoxia. Tumor hypoxia is a well substantiated poo r prognostic factor for 
multiple tumor types and increases tumor cell radioresistance. A several week course of 
fractionated radiation therapy can partially mitigate tumor hyp oxia because death of well 
oxygenated tumor cells allows for reoxygenation of more hypoxic  clonogens in a tumor. 
The efficacy of SBRT or hypofractionated regimens are suscetibl e to tumor hypoxia 
because treatment is delivered in an abbreviated course not all owing for tumor 
reoxygenation. A normoxic and hypoxi c tumor selective radiosens itizer in combination 
with SBRT would hypothetically over come barriers to intratumora l hypoxia. 
4.4 Nelfinavir 
A compound ideally situated to meet the requirements as a normo xic and hypoxic tumor 
selective radiosensitizer is the HIV protease inhibitor Nelfina v i r .  T h e  f i r s t  r e p o r t  o f  a n  
antitumoral activity of an HIV protease inhibitor (HPI) was pub lished in 1999 as a case 
SBRT and Nelfinavir 
Protocol Chair:  Phuoc Tran, MD  
J12137 (NA_00069585) - May 19, 2020 
 
 
9 
 report. The normoxic radiosensitizing effect of Nelfinavir has been well characterized in 
vitro  and in vivo  and has been linked to the inhibition of phospho-Akt which is 
overexpressed in many different types of solid tumors, but not normal tissues. Nelfinavir 
can radiosensitize hypoxic cells wi thin a tumor by decreasing H IF-1α expression and 
vascular endothelial growth fact or (VEGF) release resulting in angiogenesis inhibition and 
improved tumor oxygenation. Nelfinavir also sensitizes endothel ial cells to radiation-
induced death. Finally, utilizati on of Nelfinavir (Viracept; F.  Hoffmann-La Roche Ltd, 
Basel, Switzerland) as an anticancer agent would have the advan tage that the drug has 
already been used for more than a decade in the clinic and its safety profile is well defined. 
Retrospective data from HIV positive patients taking routine do ses of HPIs concurrently 
during conventional radiation th erapy suggests no increased nor mal tissue toxicity. (37, 
38) 
4.5 Rationale for Use in Pulmonary Metastasis 
Pulmonary tissue represents a fertile area for metastatic seedi ng from epithelial 
malignancies. Aggressive managemen t with surgical resection has  resulted in good 
outcomes. For example, in the Int ernational Registry of Lung Me tastases, over 5000 cases 
of lung metastasectomy are recorded.  
 
Multiple series have shown local control for primary lung tumor s of >90% using 
stereotactic body radiotherapy in  medically inoperable patients .(16-19)(20) A related series 
compared outcomes of wedge resection versus SBRT in primary lun g cancer and found 
improved local control with SBRT.(21) These studies report acce ptable toxicity profiles 
with a low risk of grade III or greater toxicity. Consequently,  two randomized trials are 
investigating the role of SBRT versus surgery in medically fit patients. This includes the 
Dutch ROSEL trial which randomizes operable stage T1N0 patients  to surgery versus 
SBRT as well as the STARS trial which randomizes operable stage  1 (<4cm) patients to 
surgery versus SBRT.  
 
Taken together, less invasive techniques such as SBRT are now b eing applied in place of 
metastasectomy in oligometastatic disease to target pulmonary m etastasis. Multiple 
institutions have reported favorable outcomes using either sing le or multi-fraction SBRT 
for oligometastatic sites within  the lung. Wulf et al. prescrib ed 26 Gy in single fraction and 
reported a 90% local control at 9 months.(22) Hof and colleague s report 63% progression 
free survival at 3 years using 12-30 Gy prescribed to the isoce nter.(23)  Le treated primary 
early stage and metastatic lung tumors with SBRT using doses of  15-30 Gy and report a 
local control of 91% for doses gr eater than 20 Gy and 54% for d oses less than 20 Gy.(11) 
 Single dose fraction of 15 Gy with SBRT to the lung is used to allow for acceptable toxicity 
and to meet dose constraints when multiple pulmonary targets ar e treated.  Single dose 
SBRT is limited by treatment toxicity at higher doses. Le and c olleagues report a 12.5% 
rate of grade 2 to 3 pneumonitis and a 9.4% rate of possible tr eatment related death when 
single SBRT doses of greater tha n 25 Gy were given. However, to xicity was rare when 
doses of less than 25 Gy were given.(11) The potential for mult iple targets in the 
oligometastatic setting results in difficulty in achieving pulm onary tissue constraints when 
SBRT and Nelfinavir 
Protocol Chair:  Phuoc Tran, MD  
J12137 (NA_00069585) - May 19, 2020 
 
 
10 
 doses of >25 Gy are applied to each target. An attractive alter native is to dose reduce 
radiation while giving a  radiation sensitizer.   
 A dose of 15 Gy will allow for safe targeting of multiple pulmo nary metastases.  
Radiosensitizing effects of Nelfi navir may improve local contro l to mirror those results 
with higher dose radiation while  providing acceptable toxicity.  To date, there is no 
literature to suggest an increased rate of pneumonitis or other  pulmonary toxicity with 
concurrent administration of  Nelfinavir and radiation. 
 Reports of SBRT in pulmonary metastasis are heterogeneous. Most  reports of metastatic 
lung tumors include medically inoperable patients with a primar y lung malignancy. While 
some groups report equivalent out comes, others reports decrease d local control with 
metastatic versus primary lung cancer. For example, Le et al., report a 1 year freedom from 
local relapse of 92% for primary NSCLC compared with 44% for me tastatic lesions with 
doses >20 Gy are given.(11) Additionally, series report a heter ogeneous dose of radiation 
given, making direct comparisons by dose difficult. However, ea rly reports of control do 
provide a basic framework from which to compare the efficacy of  Nelfinavir with SBRT 
compared to those treated wit h higher doses of RT alone.  
4.6 Rationale for Use in Liver Metastasis 
The primary management of unresectable metastatic disease to th e liver is systemic 
chemotherapy. Some uncontrolled tr ials have investigated liver- directed therapies such as 
transarterial embolization (TACE) , radioembolization, stereotac tic body radiation therapy 
(SBRT), chemoradiation (CRT), radiofrequency ablation, and cryo therapy in the palliative 
or, in rare cases, neoadjuvant setting(15, 24-27). Liver metast ases are a common source of 
cancer morbidity and mortality a nd are often the only site of m etastases. Major 
advancements in radiation treatment planning and delivery have resulted in resurgence in 
the use of radiation th erapy (RT) as a treatment for liver tumo rs. With the development of 
3-dimensional conformal radiati on treatment (CRT), partial live r irradiation became 
possible. Stereotactic body radiat ion therapy (SBRT) is defined  as highly focused, 
stereotactic localized, high-dos e RT delivered in a hypofractio nated course. In selected 
patients, very high local control rates have been observed, wit h minimal toxicity. Patients 
most likely to benefit from RT are those with liver confined di sease, focal distribution of 
metastases, and metastases more than 1.5 cm from luminal gastro intestinal organs.  
 Chemotherapy and molecular-target ed agents rarely eradicate met astases permanently. For 
colorectal carcinoma liver metastases, selected resection serie s have yielded 5-year 
survival rates of approximatel y 50% showing that local therapy has the potential to cure 
“oligo” or isolated liver metastases (5, 9, 28-31). Patients ar e not suitable for resection 
because of medical or surgical reasons. The benefit of local th erapy in non-colorectal liver 
metastases is less clearly defined, but long-term survival has been reported after the 
resection of liver metastases fr om sarcoma, breast cancer, and other tumor sites (32). 
 The dose-limiting toxicity from whole-liver RT is radiation-ind uced liver disease (classic 
RILD), initially called radiation hepatitis
 (33-35)and characterized pathologically by 
central vein occlusion as described by Reed and Cox.(36)With th e advent of 3-dimensional 
SBRT and Nelfinavir 
Protocol Chair:  Phuoc Tran, MD  
J12137 (NA_00069585) - May 19, 2020 
 
 
11 
 conformal radiation treatment (C RT) planning and delivery techn ology that allows for 
partial liver irradiation, and that higher tumor doses could be  delivered safely as long as 
the mean dose to the liver was kept to less than safely tolerat ed whole-liver doses. At the 
University of Michigan, no cases of RILD after CRT for colorect al liver metastases were 
seen when the mean liver dose was <31 Gy in 1.5 Gy twice a day.  This group also found 
the Lyman normal tissue complication probability model useful a s a means of relating 
dose-volume histogram data to risk of liver toxicity (35). In r ecent years, the  application of 
stereotactic body radiation ther apy (SBRT) has allowed even mor e intensive tumor dose 
escalation in a hypofractionated schedule with increased confor mality that limit the dose 
to the liver usually well belo w the threshold above which sever e RILD is observed(15). 
 It is now recognized that some pa tients with “oligo,” or few si tes of metastases, may have 
isolated sites of metastases that can be potentially cured with  local therapy. The term 
“oligometastases” was coined to refer to this stage of distant metastases.
 Typically, the 
entire burden of disease can be recognized as a finite number o f discreet lesions. Although 
there is no strict definition of oligometastases, it is commonl y interpreted to be no more 
than 5 or 6 metastatic sites. Milano et al. (9)from the Univers ity of Rochester have also 
shown that the net tumor burden for patients with 5 or fewer si tes of macrometastatic 
disease, treated on 2 prospectiv e SBRT protocols, was an indepe ndent predictor of overall 
outcome. Whether SBRT, as an adjunct to s ystemic therapy, to selected ma croscopic 
metastases can influence overall survival by keeping the burden  of disease below such a 
“lethal threshold” i s being investigated. 
 Goodman et al.(15) reported a phase I dose-escalation single-fr action trial for patients with 
liver metastases or intrahepatic cholangiocarcinoma. Doses were  escalated in 4-Gy cohorts 
from 18 Gy up to 30 Gy in 1 fraction. Twenty-six patients with 40 lesions were treated. 
There was no dose-limiting toxicity. The median follow-up was 1 7 months, and this 
corresponded to a 12-month local control rate of 77%. The 2-yea r actuarial survival rate 
was 50.4%.   Based on data above, in this study we will evaluate whether a N elfinavir plus a single 
fraction of SBRT can be combined with Nelfinavir to control liv er metastases with up to 5 
liver metastases. Patients will be closely monitored for grade 3 or above liver toxicity 
including RILD. 
4.7 Concurrent SBRT and Nelfinavir 
The use of radiation therapy to treat metastatic tumors is well  established and promising 
data are emerging with the use of SBRT for metastatic disease. However, the use of a single 
large fraction concurrent with a radiosensitizer as is being pr oposed is not of proven 
benefit. This investigation aims to confirm the safety and effi cacy for SBRT used 
concurrently with a radiosensitizer in the setting of oligometa static disease. The dose 
selected has been chosen with the belief that it is safe and ef fective based on prior 
experience with SBRT of lung cancer, pancreatic cancer and brai n radiosurgery. All 
patients will be treated with a  single fraction, targeted to th e lesion concurrently with the 
radiosensitizer Nelfinavir.  
SBRT and Nelfinavir 
Protocol Chair:  Phuoc Tran, MD  
J12137 (NA_00069585) - May 19, 2020 
 
 
12 
 On the basis of this preclinical evidence, we propose a phase I -II study of Nelfinavir 
combined with SBRT in patients with oligometastatic disease. Be cause the standard dose 
of Nelfinavir for HIV patients is known to be safe and does inh ibit the phosphorylation of 
Akt and decrease tumor hypoxia, we propose to study this in con junction with a 15 Gy 
dose of SBRT. Experien ce with single-fraction pulmonary and pan creas SBRT provides a 
useful dose for this trial.  With published data establishing the relative safety of large s ingle-
fraction SBRT to the lungs and pancreas, we have decided to pro ceed to determine the 
s a f e t y  o f  1 5  G y  S B R T  c o n c u r r e n t l y  w i t h  t h e  r a d i o s e n s i t i z e r  N e l f inavir. Once this is 
established, we propose to conti nue to enroll more patients to the study at this dose to 
determine the efficacy of this type of therapy.  
In general metastatic disease carries an extremely high mortali ty rate. Current therapies 
provide only partial palliation of  symptoms and mild to moderat e prolongation of survival. 
Patients are rarely cured of this disease; consequently, better  treatment is clearly needed. 
The proposed treatment represents a logical extension of the cu rrent state-of-the-art 
radiation therapy. It has the pot ential to translate into more effective palliation and longer 
patient survival. Another advantag e to the patient is that seve ral weeks of radiation therapy 
can be accomplished in a single day, which is not inconsequenti al for patients with a limited 
life expectancy. 
 
The proposed study represents an informed estimate based on cur rent knowledge of SBRT 
doses and those administered in currently approved image-guided  protocols (brain, base of 
skull, cervico-thoracic spine,  pancreas and liver). This study will refine the current 
understanding of single fraction radiation tolerance for normal  tissues, thereby making it 
possible to treat future patient s more safely and aggressively.  
 
5. PARTICIPANT SELECTION AND ENROLLMENT PROCEDURES  
 
All patients will be eligible to receive chemotherapy alone or conventional chemo-radiotherapy at 
the time of clinical or radiographic disease progression or at 4 w eeks post-treatment.   
 
SBRT and Nelfinavir 
Protocol Chair:  Phuoc Tran, MD  
J12137 (NA_00069585) - May 19, 2020 
 
 
13 
 5.1 Inclusion Criteria  
5.1.1 Patient’s tumor(s) to be tre ated is(are) ≤ 5.0 cm or ≤250 cm3 
5.1.2 Patient must have metastasis at one or more of the following si tes: bone, liver, lymph 
node and/or lung. No more than fiv e lesions will be treated. 
5.1.3 Histological confirmation of mali gnancy (primary or metastatic tumor). 
5.1.4 Patient may have any prior ther apy allowed aside from having ha d prior radiotherapy 
to the treatment site (see exclusion cr iteria 5.2.3). 
5.1.5 Patient must be ≥ 18 years of age. 
5.1.6 Patient must have a life expectancy ≥ 9 months.  
5.1.7 Patient must have an ECOG performance status ≤ 2.   
5.1.8 Patient must have normal organ a nd marrow function as defined a s: 
Leukocytes >2,000/μL 
Absolute Neutrophil Count >1,000/μL 
Platelets  >50,000/μL 
5.1.9 Patient must have the ability to understand and the willingness  to sign a written 
informed consent document. 
5.2 Exclusion Criteria 
5.2.1 Patient has had chemotherapy or radiotherapy within 2 weeks (6 weeks for 
nitrosoureas, anti-angiogenic age nts, or mitomycin C) prior to entering the study or 
those who have not recovered from adverse events due to agents administered more 
than 4 weeks earlier. 
5.2.2 Patient receiving any other i nvestigational agents. 
5.2.3 Patient who has had any prior radi otherapy to the treatment sit e(s). As in, definitive 
therapy for lesion of interest. F ield overlap from previous tre atment is permitted at the 
discretion of the treat ing investigator. 
5.2.4 Patient is taking concurrent drugs  that are contraindicated wit h Nelfinavir, including 
any of the following: 
Alfuzosin 
Cisapride Sildenafil (Revatio®) Amiodarone Quinidine Rifampin Dihydroergotamine 
SBRT and Nelfinavir 
Protocol Chair:  Phuoc Tran, MD  
J12137 (NA_00069585) - May 19, 2020 
 
 
14 
 Ergonovine 
Ergotamine Methylergonovine Hypericum perforatum (St. John's wort) Lovastatin Simvastatin Pimozide Midazolam  Triazolam Oral Midazolam 
5.2.5 Patient refuses to take a pregna ncy test prior to treatment if the patient is a woman 
with child bear ing potential.   
5.2.6 Patient is participating in a conc urrent treatment protocol.  
5.2.7 Patient is a pregnant woman (pre gnant women are excluded from t his study because 
radiation treatment has known  potential for teratogenic or  abortifacient effects). 
5.2.8 Patient refusesto sign informed consent. 
5.2.9 Patient has poor liver function (>2.5 times normal of ALT/AST/A lk phos) suggestive 
of cirrhosis or steatohepatitis. 
5.2.10  Patient has been treated with Nel finavir within 3 months of ent ry into this trial. 
5.2.11  Patient is receieving Warfarin (Coumadin). 
 
6. TREATMENT PLAN 
6.1 Diagnostic Procedures 
A CT scan or MRI will be performed for tumor localization using  rigid immobilization 
appropriate for stereotactic tr eatment. A separate PET-CT may b e performed (all are 
optional)  for diagnostic purposes and can be used for treatmen t planning with fusion -- 
this study would be done identica lly if the patient were having  standard moderate dose 
radiation.   
6.2 Therapeutic Procedures 
Upon confirmation of eligibility a nd enrollment in the study, t he following will be 
completed: 
1) Demographics review, medic al history and clinical exam 
2) Review of concurrent medications 
3) Vital signs, height and weight 
4) CBC, chemistry panel an d coagulation profile 
SBRT and Nelfinavir 
Protocol Chair:  Phuoc Tran, MD  
J12137 (NA_00069585) - May 19, 2020 
 
 
15 
 5) Peripheral blood mononuclear cells will be collected and subseq uently assayed for 
phospho-Akt before administration of Nelfinavir, on the day of SBRT, and optionally 
at the 1MFU. 
6) CT or MRI of the involved site( s) (if not previously conducted within 1 month of start 
of Nelfinavir). 
7) Positron Emission Tomography scan (optional) (if not previously  conducted within 1 
month of start of Nelfinavir). 
 Upon entry into the protocol, all  patients will be seen by at l east one of the Co-Investigator 
Radiation Oncologists. CT simulation will be performed with fab rication of a radiation 
therapy immobilization device (such as the Alpha Cradle) which will be custom made for 
each patient. The treating radiation oncologist will identify t he location of the tumor. Gross 
tumor volume (GTV) delineation will be performed with a diagnos t i c  r a d i o l o g i s t  o n  
sequential axial computed tomography images. A radiosurgical tr eatment plan will be 
developed based on tumor geometry and location. The dose will b e prescribed to the 
minimal isodose line that completely covers the GTV plus a 5 mm  margin. Adjacent normal 
structures including but not limited to the heart, esophagus, a orta, spinal cord, kidneys, 
rectum, bowel, liver, and stomach within 5 cm of the GTV will b e identified for the purpose 
of limiting incidental radiat ion to these structures. 
 In addition, prior to treatment delivery, a four-dimensional co ne beam CT study will be 
performed on individual patients to assess respiration in these  patients and to determine 
tumor targeting accuracy for thos e tumors that may be subject t o respiratory motion such 
as those in the lung or liver. If  tumor motion is greater than 5 mm, the planning target 
volume (PTV) will be expanded t o account for respiration. 
 Within three weeks of the initial treatment planning imaging st udy, SBRT will be 
administered using image-guidanc e. An Alpha Cradle (or equivale nt immobilization 
device) will be used to minimize movement of the chest, spine, and abdomen during 
treatment. During treatment, real time cone beam CT images of t he patient’s body site of 
interest will be obtained. Cone beam CT scan will be obtained i mmediately prior to 
treatment and will be repeated until the treatment shift, requi red to align the CT planning 
scan and the cone beam CT scan performed on the day of treatmen t cone beam CT, is 
within tolerance for the body site.  
 The patient will begin on 1250 mg oral Nelfinavir twice a day f or seven days prior to 
starting SBRT. Once having completed the Nelfinavir, the patien t will begin SBRT. 
Afterwards, the patient will again take Nelfinavir for 7 days. If scheduling or safety 
prevents all lesions from being irradiated within one day, part icipants will complete Cycle 
#2 of Nelfinavir then undergo a minimum of 7 days “clear out”. Following this break 
participants will repeat Cycle #1 of Nelfinavir then receive ra diation to the remaining 
lesions followed by a repeat Cycle #2 of Nelfinavir. This proce ss may not exceed three 
“rounds” of treatment (NFV1, SBRT, NFV2) and may include repeat  imaging and/or blood 
work.. This dose of Nelfinavir ha s been shown to reliably inhib it Akt phosphorylation. 
SBRT and Nelfinavir 
Protocol Chair:  Phuoc Tran, MD  
J12137 (NA_00069585) - May 19, 2020 
 
 
16 
  
Patients will be evaluated for a dverse events/toxicities during  their treatment. 
6.2.1 The dose limits for surrounding cri tical structures are as foll ows: 
 Spinal Cord : maximal allowable dose should be = 1000 cGy in 1 fraction  
 Lung : 2/3 of the lung volume should be kept under 500 cGy. 
 Heart : 50 % of the heart volume sh ould be kept under 1000 cGy. 
 Esophagus : 50 % of the esophagus volume should be kept under 1000 cGy an d 
no single point dose in the e sophagus should exceed 2000 cGy. 
 Brachial Plexus : maximal allowable point dose = 1000 cGy 
 Liver : One third of the uninvolved li ver or approximately 700 cc <15  Gy.  
 Kidneys:  75% of volume of each kidney <5 Gy. 
 Small Bowel:  <5% of bowel limited to <20 Gy. 
6.3 Follow-Up Procedures 
Subsequent to SBRT, patients will be followed clinically for to xicity and interval history 
at Months 1, 2, 3 6, 12, and every 6 mont hs thereafter until 3 years post SBRT. A detailed 
medical and physical examination will be performed at 4 weeks, 3 months, 6 months and 
1 year post SBRT. The following procedures are optional at Mont hs 1, 3, 6 and every 6 
months through 3 years post SBRT: 
 A complete blood count (CBC) and comprehensive chemistry panel  
 CT scan or MRI including the trea ted site  (Note: this is requi red at Months 3 and 
6 for the reason noted below) 
 Physicial Exam and ECOG Performance Status 
 
PET-CT will be recommended at 3 months, 6 months, and annually thereafter however all 
are optional.  
 CT scans at 3 and 6 months will be used to determine radiograph ic response based on 
RECIST 1.1 criteria.  
All follow-ups may be conducted by telephone for patient conven ience.  Study staff will 
request any of the optional procedures noted above that were pe rformed by local phsicians 
to be forwarded for study records. 
6.4 Duration of Therapy  
The patient will initiate Nelfinavir oral therapy twice daily s even days prior to SBRT. 
Within three weeks of the initial treatment planning imaging st udy, SBRT will be 
administered in a single dose to  each treated lesion. After com pletion of SBRT a second 
seven day cycle of Nelfi navir will occur. 
 
If scheduling or safety prevents all lesions from being irradia ted within one day, 
participants will complete Cycle #2 of Nelfinavir then undergo a minimum of 7 days “clear 
out”. Following this break participants will repeat Cycle #1 of  Nelfinavir then receive 
radiation to the remaining lesions followed by a repeat Cycle # 2 of Nelfinavir. This process 
SBRT and Nelfinavir 
Protocol Chair:  Phuoc Tran, MD  
J12137 (NA_00069585) - May 19, 2020 
 
 
17 
 may not exceed three “rounds” of treatment (NFV1, SBRT, NFV2) a nd may include repeat 
imaging and/or blood work.. 
6.5 Duration of Follow-Up 
It is anticipated that th is study will last 3 years.  
6.6 Criteria for Patient Removal 
Unacceptable adverse events grade IV or greater with an attribu tion of possibly related 
while on Nelfinavir before SBRT.  
6.7 Alternatives 
The study has been designed (see above) to minimize potential r isks to participants. This 
is primarily through designation of a dose shown to be safe in previous SBRT trials and 
careful patient monitoring. The risk of Nelfinavir is minimal a s has been documented for 
greater than a decade following FDA approval in post-market sur veillance. Risks to 
confidentiality will be minimized by having access to study rec ords avaialble only to the 
investigators with the excepti on of the standard clinical recor ds (lab values, dictations, 
operative notes, etc) which are m aintained through the Weinberg  Comprehensive Cancer 
Center.  Standard therapies for metastatic disease include conventional radiotherapy, 
chemotherapy, or observation. Such treatment may or may not be applicable for patients 
enrolled in this study. Regardless, patients will be expected t o forgo standard chemotherapy 
or radiotherapy until there is evidence of clinical or radiogra phic disease progression or 
until completion of a 4-week post-treatment evaluation.  The amount of radiation administered via protocol therapy will be considered in 
determining how much additional radiation can be given using co nventional external beam 
fractionation. 
6.8 Costs 
Patients and/or their insurance companies will be responsible f or the cost of all procedures 
and treatments under this proto col except the study drug nelfin avir. Nelfinavir will be 
supplied to the part icipant at no cost. 
6.9 Compensation 
Patients and/or their insurance companies will be responsible f or the cost of all procedures 
and treatments under this protocol. 
SBRT and Nelfinavir 
Protocol Chair:  Phuoc Tran, MD  
J12137 (NA_00069585) - May 19, 2020 
 
 
18 
 6.10 Withdrawal from Study 
The reasons for withdrawal  from the study include:  
 Subject withdraws consent for follow-up. 
 Subject is lost to follow-up. 
 Study is terminated for any reason. 
 If participants withdraw from the study, they will be followed  for survival data. 
7. INVESTIGATIONAL AGENT/DEVIC E/PROCEDURE INFORMATION 
7.1 Investigational Agent 
Nelfinavir is the commerciall y available agent being used in th is study. 
7.2 Availability 
Nelfinavir will be ordered and obt ained from the Johns Hopkins Pharmacy. 
7.3 Agent Accountability 
Only subjects enrolled in the study may receive Nelfinavir, in accordance with all 
applicable regulatory requirements. Subjects enrolled on the st udy will self-administer 
nelfinavir and keep track of their dosing intake via a study dr ug administration record. 
Nelfinavir will only be dispensed to the patient when the treat ing physician involved in the 
study provided a written order. 
8. DOSING DELAYS/DOSE MODIFICATIONS 
There will be no dose modifications. 
9. CORRELATIVE/SPECIAL STUDIES 
9.1 Assessment of Phospho-Akt 
9.1.1 A blood sample (plasma and serum) will be obtained by venipunct ure into a vacutainer 
coated with 3.2% sodium citrate an ticoagulant before Nelfinavir  administration, on the 
day of SBRT treatment, and optionally at the 1MFU. The samples will be centrifuged 
within 30 minutes of collection a nd processed in preparation fo r phosphor-akt assay 
then stored at -80°C for future analysis. 
9.1.2 The study coordinator will transport the specimen to the labora tory of Phuoc T. Tran, 
M.D., PhD for storage and processing. 
9.1.3 Specimen will be labeled by patient case ID to protect patient privacy
SBRT and Nelfinavir 
Protocol Chair:  Phuoc Tran, MD  
J12137 (NA_00069585) - May 19, 2020 
 
 
19 
 10. STUDY CALENDAR 
Parameter Pre-
Study NFV^ 
Cycle #1 SBRT
~ NFV^  
Cycle #2 Follow-Up% 
1M 
(+/- 5 
days) 2M 
(+/- 7 days) 3Mi 
(+/- 7 
days) 6M@, h, i 1 2 M@,i 1 8 M@,i 2 4 M@,i 3 0 M@,i 3 6 M@,i 
Informed 
Consent X              
Demographics X              
Med HX & 
Medication Rev  X    X  X X X X X X X 
Physical Exam X    X  X X X X X X X 
Vital Signs X    X         
Height X    X         
Weight X    X         
Perf Status X  X  X X X X X X X X X 
CBC w/ Diffa Xf    X   X  X  X  X  X  X  X  
Serum Chemb Xf    X   X  X  X  X  X  X  X  
Coagulation 
Profile Xf             
Blood Draw for 
Phospho-Akt Xf  X   X *          
CT or MRIh 
(of Involved Site(s)c) Xf    X   X  X  X  X  X  X  X  
PET-CT* Xf      X X  X  X  
CT-Guided 
Fiducial 
Placement* X              
AE Evaluationg X Xd  Xd X  X  X  X  X  X  X  X  X  
B-HCGe X              
^ Nelfinavir (NFV):  to be administered in two cycles (1250 mg BID (orally) for 7 d ays/cycle). Cycle #1 will concl ude the day prior to SBRT. Cycle  #2 will initiate the day aft er completion of SBRT.  
~ SBRT:  to be administered in one day. However, if scheduling or safet y prevents all lesions from being irradiated within one day, pa rticipants will complete Cycle #2 of Nelfinavir then undergo a 
minimum of 7 days “clear out”. F ollowing this break participant s will repeat Cycle #1 of Nelfinavir then receive radiation to the remaining lesions followed by a repeat Cycle #2 of Nelfinav ir. This 
process may not exceed three “r ounds” of treatment (NFV1, SBRT,  NFV2) and may include repeat imaging and/or blood work. Accord ingly, the study calendar will be affected.  
% Follow-up appointments will be s cheduled based on date of SBRT  completion. 
* indicates optional  
@ +/- 30 days 
a. Including platelets. 
b. Albumin, Alkaline Phosphatase, Total Bilirubin, Bicarbonate, BU N, Calcium, Chloride, Creatinine, Glucose, Potassium, Total Pro tein, SGOT [AST], SPGT [ALT], Sodium. 
c. Tumor measurements are to be cal culated after all radiographic tests. 
d. Will occur on the last d ay of Nelfinavir Cyc le #1 or on date of  SBRT administration and the last  day of Nelfinavir Cycle #2. M ay be conducted via phone. 
e. Serum pregnancy test (women of childbearing potential).  
f. Should occur within 30 days of start of Nelfinavir. 
SBRT and Nelfinavir 
Protocol Chair:  Phuoc Tran, MD  
J12137 (NA_00069585) - May 19, 2020 
 
 
20 
 g. Follow up AE evaluations m ay be conducted via phone. 
h. Required at 3 and 6 months  
i. May be conducted via telephone.  All procedures are optional , EXCEPT for interval history a nd AE evaluations.  Study staff will remind subjects of upcoming optional procedures at each te lephone 
or follow-up visit.  If obtaine d locally, staff will request th at the results be forwarded for study records. 
SBRT and Nelfinavir 
Protocol Chair:  Phuoc Tran, MD  
J12137 (NA_00069585) - May 19, 2020 
 
 
21 
 11. MEASUREMENT OF EFFECT 
11.1 Antitumor Effect-Solid Tumors 
For the purposes of this study, patients should be re-evaluated  for response 4 weeks after 
the initial treatment, 12 weeks after treatment, 24 weeks after  treatment, and every 24 
weeks thereafter.   Response and progression will be evaluated in this study using the new international 
criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) 
Committee (30). Changes in only the largest diameter (unidimens ional measurement) of 
the tumor lesions are use d in the RECIST criteria. 
11.2 Definitions 
Evaluable Population: will consist of all patients who have rec eived 28 doses of Nelfinavir 
treatment preceding SBRT. 
Safety Population: Will consist of all subjects who were enroll ed and have taken at least 
one dose of the study medication. This will be used to assess t he clinical safety and 
tolerability of the study. 
 
Evaluable for Objective Response: Only those patients who have measurable disease 
present at baseline, have completed all fractions of SBRT, and have had their disease re-
evaluated will be considered eva luable for response. These pati ents will have their response 
classified accordi ng to the definitions stated below.  
11.3 Disease Parameters 
Measurable Disease: Measurable lesions are defined as those tha t can be accurately 
measured in at least one dimension (longest diameter to be reco rded) as >10 mm with 
diagnostic techniques (CT, PET/CT (all are optional), or MRI). All tumor measurements 
must be recorded in millimeters (or decimal fractions of centim eters). 
 
Non-Measurable Disease: All other lesions (or sites of disease) , including small lesions 
(longest diameter <10 mm with diagnostic techniques), are consi dered non-measurable 
disease. Bone lesions, leptomeningeal disease, ascites, pleural /pericardial effusions, 
lymphangitis, inflammatory breast disease, abdominal masses (no t followed by CT or 
MRI), and cystic lesions a re all non-measurable. 
 
Target Lesions: Target lesions i n this study will be considered  oligometastatic sites up to 
a maximum of 5 lesions per patient. They should be recorded and  measured at baseline. 
Target lesions should be equal to or larger than 10 mm in the s mallest cross-sectional 
diameter on CT or MRI and/or any  lesion that shows increase met abolic uptake on PET/CT 
scans. A sum of the longest diameter (LD) for all target lesion s will be calculated and 
reported as the baseline sum LD. The baseline sum LD will be us ed as reference by which 
to characterize the obj ective tumor response. 
 
SBRT and Nelfinavir 
Protocol Chair:  Phuoc Tran, MD  
J12137 (NA_00069585) - May 19, 2020 
 
 
22 
 Non-Target Lesions: N/A 
11.4 Methods for Evaluation of Measurable Disease 
All measurements should be taken and recorded in metric notatio n using a ruler or calipers. 
All baseline evaluations should be performed as closely as poss ible to the beginning of 
treatment and never more than 4 weeks before the beginning of t he treatment. 
 
The same method of assessment and the same technique should be used to characterize 
each identified and reported lesion at baseline and during foll ow-up. Imaging-based 
evaluation is preferred to evaluation by clinical examination w hen both methods have been 
used to assess the antitumo r effect of a treatment. 
 
Conventional CT, PET/CT (all are optional), and MRI These techn iques should be 
performed with cuts of 10 mm or l ess in slice thickness contigu ously. Spiral CT should be 
performed using a 5 mm contiguous reconstruction algorithm. Thi s applies to tumors of 
the chest, abdomen, and pelvis. Head and neck tumors and those of extremities usually 
require specific protocols. 
11.5 Response Criteria (via RECIST 1.1) 
11.5.1  Evaluation of Target Lesions  
Complete Response (CR):  Disapp earance of all target lesions 
 
Partial Response (PR):    At least a 30% decrease in the sum of  the longest diameter 
(LD) of target lesions, taking as reference the baseline sum 
LD 
 
Progressive Disease (PD):   At least a 20% increase in the sum of the LD of target 
lesions, taking as reference the smallest sum LD recorded 
since the treatment started or the appearance of one or more new lesions 
 
Stable Disease (SD):    Neither sufficient shrinkage to qualify  for PR nor sufficient 
increase to qualify for PD, taking as reference the smallest 
sum LD since the treatment started 
11.5.2  Evaluation of Non-Target Lesions 
N/A 
11.5.3  Evaluation of Best Overall Response 
The best overall response is the best response recorded from th e start of the treatment 
until disease progression/recurrence (taking as reference for p rogressive disease the 
smallest measurements recorded since the treatment started). Be st overall response will 
be based on the overall response of the target lesions. 
SBRT and Nelfinavir 
Protocol Chair:  Phuoc Tran, MD  
J12137 (NA_00069585) - May 19, 2020 
 
 
23 
 11.5.4  Duration of Response 
Response will be defined as evidence of CR, PR, or stable disea se. The duration of 
response will be measured from the start of treatment until the  criteria for progression 
are met.   Duration of CR or PR: The duration of CR or PR will be recorded  from the time 
measurement criteria are met for CR or PR (whichever is first r ecorded) until the first 
date that current or progressive  disease is objectively documen ted (taking as reference 
for progressive disease the smallest measurements recorded sinc e the treatment 
started). 
 
Duration of Stable Disease: Stable disease is measured from the  start of the treatment 
until the criteria for progression are met, taking as reference  the smallest measurements 
recorded since the treatment started.  
11.5.5  Clinical Response Parameters 
 
Time to Local Progression (TTLP) is defined as the elapsed time from the start of 
treatment to the date of documen ted local progression or death,  whichever happens 
earliest.   
Progression-Free Survival (PFS)  is defined is the time from starting treatment to the 
time of first documented tumor progression or death due to any cause, whichever 
occurs first. Death is considered as an event here . For subject s whose dise ase does not 
progress or who do not die, PFS will be censored at the time of  the last visit.  
Time to Progression (TTP)  is defined as the time from starting treatment to the time 
of first documented tumor prog ression. Subjec ts who do not prog ress will be censored 
at the time of the last cont act. In addition, death from any ca use will also be censored.  
Overall Survival (OS)  is defined as the time from sta rting treatment until death due  to 
any cause. For subjects who do not die, time to death will be c ensored at the time of 
last contact. 
 
 Locoregional Control (LRC)  is defined as the time from starting treatment until local 
and/or regional relapse is documented 
11.5.6  Response Review 
All responses will be reviewed by the study co-investigator rad iologist. 
12. ADVERSE EVENT REPORTING REQUIREMENTS 
12.1 General 
Adverse event collection and reporting is a routine part of eve ry clinical trial. This study 
will use the descriptions and grading scales found in the NCI C ommon Terminology 
Criteria for Adverse Events version 4.0 (CTCAE v 4.0) that is a vailable at 
http://ctep.cancer.gov/r eporting//ctc.html.  
SBRT and Nelfinavir 
Protocol Chair:  Phuoc Tran, MD  
J12137 (NA_00069585) - May 19, 2020 
 
 
24 
  
Information on all adverse events, whether reported by the part icipant, directly observed, 
or detected by physical examination, laboratory test or other m eans, will be collected, 
recorded, followed and reported as  described in the following s ections.  
 Participants should be instructe d to report any serious post-st udy event(s) that might 
reasonably be related to particip ation in this st udy. The inves tigator should notify the IRB 
and any other applicable regulatory agency of any unanticipated  death or adverse event 
occurring after a participant has discontinued or terminated st udy participation that may 
reasonably be related to the study.  
12.2 Definitions 
12.2.1  Adverse Event (AE) 
An adverse event is any undesirable sign, symptom or medical co ndition or experience 
that develops or worsens in seve rity after starting the first d ose of study treatment or 
any procedure specified in the protocol, even if the event is n ot considered to be related 
to the study.   Abnormal laboratory values or di agnostic test results constitut e adverse events only if 
they induce clinical signs or sym ptoms or require treatment or further diagnostic tests.  
12.2.2  Serious adverse event (SAE) 
A serious adverse event is a n undesirable sign, symptom, or med ical condition which: 
 
 is fatal or life-threatening; 
 requires or prolongs inp atient hospitalization; 
 results in persistent or signi ficant disability/incapacity; 
 constitutes a congenital anomaly or birth defect; or 
 jeopardizes the participant and requires medical  or surgical intervention to prevent 
one of the outcomes listed above.  
 
Events not considered to be serious advers e events are hosp italizations fo r: 
 routine treatment or monitoring of the studied indication, not associated with any 
deterioration in condition, or  for elective procedures 
 elective or pre-planned treatme nt for a pre-existing condition that did not worsen 
 emergency outpatient treatment for an event not fulfilling the serious criteria 
outlined above and not resulting in inpatient admission 
 respite care 
12.2.3  Expectedness  
 Expected: Expected adverse events are those that have been prev iously identified 
as resulting from administration of the agent. For the purposes  of this study, an 
adverse event is considered expe cted when it appears in the cur rent adverse event 
list, the Investigator’s Brochure, the package insert or is inc luded in the informed 
consent document as a potential risk. 
SBRT and Nelfinavir 
Protocol Chair:  Phuoc Tran, MD  
J12137 (NA_00069585) - May 19, 2020 
 
 
25 
  Unexpected: An adverse event is considered unexpected when it v aries in nature, 
intensity or frequency from information provided in the current  adverse event list, 
the Investigator’s Brochure, the  package insert or when it is n ot included in the 
informed consent documen t as a potential risk 
12.2.4  Attribution  
Attribution is the relationship between an adverse event or ser ious adverse event and 
the study treatment. Attributi on will be assigned as follows: 
 
 Definite – The AE is clearly related  to the study treatment. 
 Probable – The AE is likely related  to the study treatment. 
 Possible – The AE may be related  to the study treatment.  
 Unlikely - The AE is  doubtfully related  to the study treatment. 
 Unrelated - The AE i s clearly NOT related  to the study treatment. 
12.3 Potential Adverse Events  
Signs and symptoms of disease pr ogression are not considered AE s. The development of a 
new cancer should be regarded as an AE. New cancers are those t hat are not the primary 
reason for administration of st udy treatment and have been iden tified after inclusion of the 
patient into the clinical study.  
 
Because patients are receiving standard treatments, which are n ot part of this study, their 
treating physician will be counse ling them on the risk of their  treatments, including the risk 
of surgery, radiation therapy, and/or chemotherapy, whichever i s appropriate for the type 
and the stage of their cancer. The procedures related to the st udy are phlebotomy, PET 
imaging (all are optional), SBRT, a nd Nelfinavir administration . 
 Phlebotomy can cause pain, bleeding, and rare needle site infec tion. PET imaging results 
in low dose radiation exposure ( see Investigator’s Brochure for  details of dosimetry), which 
has an extremely small risk of  causing a secondary cancer.  
12.4 Stereotactic Body Radiation Treatment 
It is difficult at this time to predict with confidence the com plication rate from the proposed 
SBRT; however, it is reasonable to extrapolate from the current  experience with SBRT to 
the lung and pancreas. One signi ficant toxicity is radiation pn eumonitis, which can be 
manifested as fever, increased  excertional dypsn ea, pleuritic c hest pain, and peritumoral 
infiltrate on chest imaging. It g enerally occurs between 1 to 3  months of completion of 
radiotherapy. The risk of grade 2-4 radiation pneumonitis is ap roximately 10-15% in 
patients treated with standard fr actionated large field radioth erapy and higher in patients 
treated with combined chemoradiotherapy. It is highly dependent  on the volume of the lung 
treated to high dose and the mean  lung dose. At this point, the  incidence of RT pneumonitis 
from stereotactic radiosurgery for small pulmonary tumors is un known. However, if the 
treated tumor volume is kept ≤  65 cc, the risk should be < 10-1 5% with the proposed dose 
level. 
 
SBRT and Nelfinavir 
Protocol Chair:  Phuoc Tran, MD  
J12137 (NA_00069585) - May 19, 2020 
 
 
26 
 Other toxicities commonly associated with such treatment includ es dysphagia, 
odynophagia, nausea, vomiting, anorexia, and weight loss. Some of these symptoms can 
also be due to tumor progression. Clinical and radiographic ass essments will be performed 
as indicated to identify all adverse effects, ascertain their e tiology, and provide the most 
appropriate palliative measures. Complications orther than radi ation pneumonitis, if any, 
will be graded according to the Common Toxicity Criteria, Natio nal Cancer Institute, 
version 4.0. 
12.5 Nelfinavir 
12.5.1  The safety of VIRACEPT (Nelfinavir mesylate) was studied in ove r 5000 patients who 
received drug either alone or in combination with nucleoside an alogues. The majority 
of adverse events were of mild intensity. The most frequently r eported adverse event 
among patients receiving VIRACEPT was diarrhea, which was gener ally of mild to 
moderate intensity. The frequenc y of Nelfinavir-associated diar rha may be increased 
in patients receiving the 625 mg tablet because of the increase d bioavailability of this 
formulation. 
 
Adverse events occurring in patients receiving VIRACEPT in all phase II/III clinical 
trials and considered at least possibly related or of unknown r elationship to treatment 
and of at least moderate severity are listed below: Body as a Whole : abdominal pain, accidental inj ury, allergic reaction, astheni a, back 
pain, fever, headache, malaise , pain, and redistribution/accumu lation of body fat. 
Digestive System : anorexia, nausea dyspepsia, ep igastric pain, gastrointestinal  
bleeding, hepatitis, mouth ulceration, pancreatitis and vomitin g. 
Hemic/Lymphatic System : anemia, neutropenia, leukope nia and thrombocytopenia. 
Metabolic/Nutritional System : increases in alkaline phospha tase, amylase, creatinine, 
phosphokinase, lactic dehydrogenas e, SGOT, SGPT and gamma gluta myl 
transpeptidase; hyperlipemia, hyperuricemia, hyperglycemia, hyp oglycemia, new 
onset or exacerbation of diabetes mellitus, dehydration, hepati tis, jaundice, and liver 
function tests abnormal. Musculoskeletal System : arthralgia, arthritis, cramps, myalgia, myasthenia and 
myopathy. Nervous System : anxiety, depression, dizziness, emotional lability, hyperkine sia, 
insomnia, migraine, paresthesia, seizures, sleep disorder, somn olence and suicide 
ideation. Respiratory System : dyspnea, pharyngitis, rhinitis, and sinusitis. 
Skin/Appendages : dermatitis, folliculitis, funga l dermatitis, maculopapular ra sh, 
pruritus, sweating, and urticaria. Special Senses : acute iritis and eye disorder. 
Urogenital System : kidney calculus, sexual dys function and urine  abnormality. 
12.5.2  The following additional adverse experiences have been reported  from post marketing 
surveillance as at least possibly related or of unknown relatio nship to VIRACEPT: 
Body as a Whole: hypersensitivity reactions (incl uding bronchospasm, moderate to  
severe rash, fever and edema). 
SBRT and Nelfinavir 
Protocol Chair:  Phuoc Tran, MD  
J12137 (NA_00069585) - May 19, 2020 
 
 
27 
 Cardiovascular System: QTc prolongation, torsades de pointes. 
Digestive System : jaundice. 
Metabolic/Nutritional System: bilirubinemia, met abolic acidosis. 
12.5.3  Human experience of acute overdose with VIRACEPT is limited. Th ere is no specific 
antidote for overdose with VIRACEPT. If indicated, elimination of unabsorbed drug 
should be achieved by emesis or gastric lavage. Administration of activated charcoal 
may also be used to aid removal of unabsorbed drug. Since Nelfi navir is highly protein 
bound, dialysis is unlikely to signi ficantly remove drug from b lood. 
12.6 Fiducial Implantation 
The risk associated with implantation of fiducials is primarily  related to the small risk of 
pneumothorax associated with percutaneous placement of a needle  within the lung. The 
procedure is analogous to percutaneous needle biopsy, a commonl y performed procedure 
which is associated with a pneumothorax risk ranging from 16-40 %. Of patients who 
develop a pneumothorax, most are managed by observation alone, with only 5-7% of 
patients requiring intervention such as chest tube placement. A nother rare risk of fiducial 
placement is exacerbation of chr onic obstructive lung disease, which may require medical 
interventions, including rare hos pitalization. Other potential complications of fiducial 
implantation is embolization. In the literature, there is littl e data regarding this potential 
complication, but if one were to extrapolate from patients suff ering gun-shot wounds to the 
chest, either with pellets or bullets, standard surgical teachi ng is not to removal of the small 
foreign bodies as they rarely cau se harm. To further avoid the potential risk of 
embolization, every effort will be made to place the fiducials in the substance of te tumor 
rather than in the adjacent lung parenchyma. Theoretically, fid ucials implanted elsewhere 
in the body could embolize to the l ungs; to date this has not b een reported. 
12.7 Reporting Procedures 
12.7.1  General 
Adverse events will be recorded at each visit. If an adverse ev ent requiring medical 
attention occurs between visits, this will be recorded as well.  The variables to be 
recorded for each adverse event include, but are not limited to , onset, resolution, 
intensity, action taken, outcome,  causality rating and whether it constitutes an SAE or 
not. The intensity of the adverse event should be captured usin g CTCAE criteria, 
version 4.0, when possible.   Pregnancy should be excluded before enrollment. Pregnancy in it self is not reported as 
an AE unless there is a suspicion that an investig ational produ ct may have interfered 
with the effectiveness of a contraceptive medication.   
All adverse events will be captured on the appropriate study-sp ecific case report forms 
(CRFs).  
SBRT and Nelfinavir 
Protocol Chair:  Phuoc Tran, MD  
J12137 (NA_00069585) - May 19, 2020 
 
 
28 
 12.7.2  Institutional Review Board 
All adverse events and serious adverse events will be reported to the IRB per current 
institutional standards. If an adverse event requires modificat ion of the informed 
consent, these modifications wil l be provided to the IRB with t he report of the adverse 
event. If an adverse event requires modification to the study p rotocol, these 
modifications will be provided t o the IRB as soon as is possibl e. 
13. DATA AND SAFETY MONITORING PLAN  
This is a DSMP Level I study under the SKCCC Monitoring Plan (s ee Appendix II). A Level I study 
requires both internal and exte rnal data monitoring. The Princi pal Investigator is responsible for 
internal monitoring for both safety and data quality. External data monitoring will be performed by 
the SKCCC at Johns Hopkins Clinic al Research Office Quality Ass urance Program (CRO QA).  
 
Data and safety monitoring oversight will be conducted by the S KCCC at Johns Hopkins Safety 
Monitoring Committee. Per the SKCCC at Johns Hopkins Safety Mon itoring plan, the CRO AQ will 
forward summaries of all monitoring reports to the Safety Monit oring Committee for review. All 
reportable anticipated and unantic ipated protocol events/proble ms and amendments that are 
submitted to the IRB will also be reviewed by the Safety Monito ring Committee Chair (or designee) 
and QA manager. 
 
14. REGULATORY CONSIDERATIONS 
14.1 Protocol Review and Amendments 
 
Information regarding study conduct and progress will be report ed to the Institutional 
Review Board (IRB) per the current institutional standards.  Any changes to the protocol will be made in the form of an amen dment and must be 
approved by the IRB prior to implementation.   
14.2 Informed Consent 
The investigator (or his/her designee) will explain to each sub ject the nature of the study, 
its purpose, the procedures involved, the expected duration, th e potential risks and benefits 
involved and any discomfort it ma y entail. Each subject will be  informed that participation 
in the study is voluntary, that she may withdraw from the study  a t  a n y  t i m e ,  a n d  t h a t  
withdrawal of consent will not affect her subsequent medical tr eatment or relationship with 
the treating physician(s) or institution. The informed consent will be given by means of a 
standard written statement, wri tten in non-technical language, which will be IRB approved. 
The subject should read and consider the statement before signi ng and dating it, and will 
be given a copy of the document. No subject will enter the stud y or have study-specific 
procedures done before his/her i nformed consent has been obtain ed. 
 In accordance with the Health Inf ormation Portability and Accou ntability Act (HIPAA), 
the written informed consent document (or a separate document t o be given in conjunction 
SBRT and Nelfinavir 
Protocol Chair:  Phuoc Tran, MD  
J12137 (NA_00069585) - May 19, 2020 
 
 
29 
 with the consent document) will include a subject authorization  to release medical 
information to the study sponsor and supporting agencies and/or  allow these bodies, a 
regulatory authority, or Institutional Review Board access to s ubjects’ medical information 
that includes all hospital records relevant to the study, inclu ding subjects’ medical history. 
 
14.3 Ethics and GCP 
This study will be carried out in c ompliance with the protocol and Good Clinical  Practice, 
as described in:  1. ICH Harmonized Tripartite Guid elines for Good Clin ical Practice  1996. 
2. US 21 Code of Federal Regulations dealing with clinical studies  (including parts 50 
and 56 concerning informed consent and IRB regulations). 
3. Declaration of Helsinki, concerning medical research in humans (Recommendations 
Guiding Physicians in Biomedical Research Involving Human Subje cts, Helsinki 1964, 
amended Tokyo 1975, Venice 1983, Hong Kong 1989, Somerset West 1996). 
 The investigator agrees to adhere to the instructions and proce dures described in it and 
thereby to adhere to the princi ples of Good Clinical Practice t hat it conforms to.   
15. STATISTICAL CONSIDERATIONS  
15.1 Endpoints 
15.1.1  Primary Objective 
To determine the 6-month freedom  from local progression of the radiosensitizer 
Nelfinavir used concurrently wit h 15 Gy of stereotactic body ra diation therapy (SBRT) 
delivered in 1 fraction (per l esion site) in pa tients with olig ometastatic disease. 
15.1.2  Secondary Objectives 
o To describe the toxicity of SBRT  combined with Nelfinavir deliv ered for the 
population enrolled using gr ading with CTCAE v. 4.0 
o To determine the local control at 6 months after SBRT is delive red to a dose of 15 
Gy in 1 fraction (per lesion rate) combined with Nelfinavir in patients with 
oligometastatic disease. 
o To assess long-term clinical out comes of this patient populatio n after completion 
of SBRT and Nelfinavir by measur ing progression-free survival a nd overall 
survival. Progression-free survival will be measured from time of enrollment to 
date of disease progression or death. Patients who are lost to follow-up will be 
censored for determination of progression-free survival on the date of their last 
evaluation. Overall surv ival is defined as time from enrollment  to death due to any 
cause.  
o To assess quality of life following completion of SBRT and Nelf inavir using pre- 
and post-SBRT completion of the Brief Pain Inventory form which  will be filled 
out by the patient at the treatm ent response intervals outlined  above.  
 
15.2 Sample Size/Accrual Rate 
The primary endpoint will be freedom from local progression at 6 months. The treatment 
regimen would be considered of insufficient activity for furthe r study in this population 
SBRT and Nelfinavir 
Protocol Chair:  Phuoc Tran, MD  
J12137 (NA_00069585) - May 19, 2020 
 
 
30 
 if the 6-month FFLP rate is 70% or less, and the minimum requir ed level of efficacy that 
would warrant further  study with the propos ed regimen is a 90% FFLP at 6 months. The 
accrual rate is 3 patients per month, and the patients will be followed for up to 3 years. 
A total of 42 patients will be entered in the study accounting for a 15% dropout rate. This 
study would have 90% power to detect an improved 6-month FFLP f rom 70% to 90% 
using a two-sided test at signi ficance level 0.05. Alternativel y, this corresponds to the 
power to detect a reduction of hazard rate from 0.06 to 0.02, a  reduction of 70% in hazard 
rate. 
There will be no interim analysis for futility, since the progr ession endpoint will not have 
been reached by a meaningful numbe r of patients before full acc rual. 
15.3 Safety Run-In Phase 
There is no previous experience with SBRT used concurrently wit h Nelfinavir in this 
study population. Therefore, to ensure that the combination is safe, the first six patients 
will be treated and observed for toxicity for 30 days after rad iation before continuing with 
further accrual. 6 patients will be enrolled at the proposed do se of Nelfinavir and SBRT.If 
≤ 2 toxicity events occur in the first 6 patients within 30 day s of therapy, we proceed with 
additional accrual with this regimen to complete a total of 42 patients. If ≥ 3 toxicity events 
occur among the first 6 patients, we will suspend the study pen ding data review. 
 Toxicity Event:  ≥grade 3 adverse event (CTCAE v  4.0) with an attribution of po ssible, 
probable, or definite. 
15.4 Early Stopping Guidelines: 
This study will monitor site-specific grade 4/5 toxicity. If it  becomes evident that the 
proportion of grade 4/5 toxicity a t specific sites convincingly  exceeds 20%, the study will 
be halted for a safety consultation. Specifically, we will appl y a Bayesian toxicity 
monitoring rule that suspends the  enrollment if the posterior p robability of toxicity being 
larger than 20% threshold is 75% or higher. The monitoring rule  uses Beta (0.5, 5.5) as 
prior distribution. This means that our prior guess of the prop ortion of toxicity is 8.3%, 
and there is 90% chance that this proportion is 0.04%-30.6%. Th e monitoring will start 
from the 7th patient, and the deci sion rule for safety stopping  is as follows: 
 
Stop if: 
 
# grade 4/5 toxicities ≥  4 5 6 7 8 9 10 
Out of # patients 7 - 10 11 - 14 15 - 18 19 - 23 24 - 27 28 - 32 33 - 36 
# grade 4/5 toxicities ≥  1 1  1 2       
Out of # patients 3 7  -  4 1  4 2       
 
The operating characteristics of  the stopping rule are shown be low and are based on 5000 
simulations: 
SBRT and Nelfinavir 
Protocol Chair:  Phuoc Tran, MD  
J12137 (NA_00069585) - May 19, 2020 
 
 
31 
 True AE rate % simulated trials 
declaring unsafe Average sample size 
(out of 42) 
0.10 2.1 41.4 
0.15 11.3 39.2 0.2 32.7 34.3 0.25 59.5 27.7 0.3 81.9 21.2 0.35 93.6 16.1 0.4 98.3 12.7 
 
15.5 Analysis of Primary Objective 
The primary efficacy analysis will estimate 6-month freedom fro m local. Freedom from 
local progression (FFLP) is defined as the elapsed time from th e start date of treatment to 
the date of documented local. Patients who die without local pr ogression will be censored 
at the time of death. We will plot the Kaplan-Meier curve for F FLP and estimate 6-month 
FFLP and its 95% confidence interval based on KM estimate and G reenwood’s formula. 
The analysis population includes all registered subjects who ha ve received at least one 
fraction of SBRT. Patients that develop distant metastasis befo re local progression will 
remain on study. 
 
15.6 Analysis of Secondary Objectives 
o For safety analysis, adverse e vents will be summarized by type and grade. 
o Hazard rate estimates and 95% confidence intervals as well as K aplan-Meier (KM) 
estimates will be used to summarize survival (OS), progression free survival (PFS), 
time to locoregional progression  (TTLP) and time to distant pro gression (TTDP), 
duration of response functions over time. The median OS, PFS, T TLP and TTDP will 
be reported.  
o The efficacy of SBRT combined with Nelfinavir with oligometasta tic disease will also 
be determined by measuring local control of each lesion at 6 mo nth. Each metastatic 
lesion will be considered a target lesion and independently eva luated for response using 
RECIST 1.1. The lesion will be co ded as being locally controlle d if it is considered 
stable radiographic disease or if there is evidence of a partia l or complete response. 
Local control assessment will start at one month following comp letion of protocol 
treatment and continuous assessment will be pursued during the follow-up period. The 
proportion of the lesions that ha ve a stable or better response  will be estimated using 
generalized estimating equation. The above analyses will also b e performed by 
metastases site (bone , liver and lung).  
o Quality of life will be assessed using the Brief Pain Inventory  form. An overall score 
will be calculated pre-treatment and at the time of the 2nd radiologic reassessment. The 
change in score will be evalu ated with a paired t-test.  
o The analysis for the correlative study will be done by Western blot. The change of 
phospho-Akt levels will be corre lated to progression-free survi val outcome.  
15.7 Evaluation of Toxicity 
All patients will be evaluable f or toxicity from the time of th eir first treatment for SBRT. 
SBRT and Nelfinavir 
Protocol Chair:  Phuoc Tran, MD  
J12137 (NA_00069585) - May 19, 2020 
 
 
32 
 15.8 Evaluation of Response 
All patients included in the  study must be assessed for respons e to treatment, even if there 
are major protocol treatment dev iations or if they are ineligib le. Each patient will be 
assigned one of the following cat egories: 1) complete response,  2) partial response, 3) 
stable disease, 4) progressive d isease, 5) early death from mal ignant disease, 6) early death 
from toxicity, 7) early death because of other cause, or 9) unk nown (not assessable, 
insufficient data). [Note: By arbitrary convention, category 9 usually designates the 
“unknown” status of any type of da ta in a clinical database.] 
 All of the patients who met the eligibility criteria (with the possible exception of those who 
received no study medication) should be included in the main an alysis of the response rate. 
Patients in response categories 4-9 should be considered to hav e a treatment failure (disease 
progression).  
 
All conclusions should be based on all eligible patients. Sub-a nalyses may then be 
performed on the basis of a subset of patients, excluding those  for whom major protocol 
deviations have been identified (e.g., early death due to other  reasons, early discontinuation 
of treatment, major protocol violations, etc.). However, these sub-analyses may not serve 
as the basis for drawing conclusions concerning treatment effic acy, and the reasons for 
excluding patients from the analysis should be clearly reported . The reason for performing 
subset analyses would be to ge nerate hypotheses for future pros pective clinical trials. 
 
SBRT and Nelfinavir 
Protocol Chair:  Phuoc Tran, MD  
J12137 (NA_00069585) - May 19, 2020 
 
 
33 
 REFERENCES: 
1. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995 Jan; 13(1): 8-10.  
2. Bacci G, Rocca M, Salone M, Balla delli A, Ferrari S, Palmeri ni E, Forni C, Briccoli A. High 
grade osteosarcoma of the extremities with lung metastases at p resentation: Treatment with 
neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions. J Surg 
Oncol. 2008 Nov 1; 98(6): 415-420.  
3. Fong Y, Cohen AM, Fortner JG, Enker WE, Turnbull AD, Coit DG , Marrero AM, Prasad M, 
Blumgart LH, Brennan MF. Liver resection for colorectal metasta ses. J Clin Oncol. 1997 Mar; 
15(3): 938-946.  
4. Steele G,Jr, Bleday R, Mayer RJ, Lindblad A, Petrelli N, Wea ver D. A prospective evaluation 
of hepatic resection for colorectal carcinoma metastases to the  liver: Gastrointestinal tumor study 
group protocol 6584. J Clin Oncol. 1991 Jul; 9(7): 1105-1112.  
5. Simmonds PC, Primrose JN, Col quitt JL, Garden OJ, Poston GJ,  Rees M. Surgical resection of 
hepatic metastases from colorectal cancer: A systematic review of published studies. Br J Cancer. 
2006 Apr 10; 94(7): 982-999. PMCID: PMC2361241.  
6. Schefter TE, Kavanagh BD, Timmerman RD, Cardenes HR, Baron A , Gaspar LE. A phase I 
trial of stereotactic body radia tion therapy (SBRT) for liver m etastases. Int J Radiat Oncol Biol 
Phys. 2005 Aug 1; 62(5): 1371-1378.  
7. Okunieff P, Petersen AL, Philip A, Milano MT, Katz AW, Boros  L, Schell MC. Stereotactic 
body radiation therapy (SBRT) for lung metastases. Acta Oncol. 2006; 45(7): 808-817.  
8. Lo SS, Fakiris AJ, Teh BS, Cardenes HR, Henderson MA, Forque r JA, Papiez L, McGarry RC, 
Wang JZ, Li K, Mayr NA, Timmerman RD. Stereotactic body radiati on therapy for 
oligometastases. Expert Rev Anticancer Ther. 2009 May; 9(5): 621-635.  
9. Milano MT, Katz AW, Muhs AG, Philip A, Buchholz DJ, Schell M C, Okunieff P. A prospective 
pilot study of curative-intent st ereotactic body radiation ther apy in patients with 5 or fewer 
oligometastatic lesions. Cancer. 2008 Feb 1; 112(3): 650-658.  
10. Milano MT, Katz AW, Schell MC, Philip A, Okunieff P. Descri ptive analysis of 
oligometastatic lesions treated with curative-intent stereotact ic body radiotherapy. Int J Radiat 
Oncol Biol Phys. 2008 Dec 1; 72(5): 1516-1522.  
11. Le QT, Loo BW, Ho A, Cotrutz C, Koong AC, Wakelee H, Kee ST , Constantinescu D, Whyte 
RI, Donington J. Results of a phase I dose-escalation study usi ng single-fraction stereotactic 
radiotherapy for lung tumors. J Thorac Oncol. 2006 Oct; 1(8): 802-809.  
SBRT and Nelfinavir 
Protocol Chair:  Phuoc Tran, MD  
J12137 (NA_00069585) - May 19, 2020 
 
 
34 
 12. Gibbs IC, KamnerdsupaI phon P, Ryu MR, Dodd R, Kiernan M, C hang SD, Adler JR,Jr. 
Image-guided robotic radiosurgery for spinal metastases. Radiother Oncol. 2007 Feb; 82(2): 185-
190.  
13. Lo SS, Fakiris AJ, Abdulrahman R, Henderson MA, Chang EL, S uh JH, Timmerman RD. Role 
of stereotactic radiosurgery and  fractionated stereotactic radi otherapy in pediatric brain tumors. 
Expert Rev Neurother. 2008 Jan; 8(1): 121-132.  
14. Levine AM, Coleman C, Horasek S. Stereotactic radiosurgery for the treatment of primary 
sarcomas and sarcoma metastases of the spine. Neurosurgery. 2009 Feb; 64(2 Suppl): A54-9.  
15. Goodman KA, Wiegner EA, Maturen KE, Zhang Z, Mo Q, Yang G, Gibbs IC, Fisher GA, 
Koong AC. Dose-escalation study o f single-fraction stereotactic  body radiotherapy for liver 
malignancies. Int J Radiat Oncol Biol Phys. 2010 Oct 1; 78(2): 486-493.  
16. Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K,  Niibe Y, Karasawa K, 
Hayakawa K, Takai Y, Kimura T, Takeda A, Ouchi A, Hareyama M, K okubo M, Hara R, Itami J, 
Yamada K, Araki T. Hypofractionate d stereotactic radiotherapy ( HypoFXSRT) for stage I non-
small cell lung cancer: Updated results of 257 patients in a ja panese multi-ins titutional study. J 
Thorac Oncol. 2007 Jul; 2(7 Suppl 3): S94-100.  
17. Baumann P, Nyman J, Hoyer M, Wennberg B, Gagliardi G, Lax I , Drugge N, Ekberg L, 
Friesland S, Johansson KA, Lund JA, Morhed E, Nilsson K, Levin N, Paludan M, Sederholm C, 
Traberg A, Wittgren L, Lewensohn R. Outcome in a prospective ph ase II trial of medically 
inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. 
J Clin Oncol. 2009 Jul 10; 27(20): 3290-3296.  
18. Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Br adley J, Fakiris A, Bezjak A, 
Videtic G, Johnstone D, Fowler J, Gore E, Choy H. Stereotactic body radiation therapy for 
inoperable early stage lung cancer. JAMA. 2010 Mar 17; 303(11): 1070-1076. PMCID: 
PMC2907644.  
19. Videtic GM, Stephans K, Reddy C, Gajdos S, Kolar M, Clouser  E, Djemil T. Intensity-
modulated radiotherapy-based st ereotactic body radiotherapy for  medically inoperable early-stage 
lung cancer: Excellent local control. Int J Radiat Oncol Biol Phys. 2010 Jun 1; 77(2): 344-349.  
20. Fakiris AJ, McGarry RC, Yiannoutsos CT, Papiez L, Williams M, Henderson MA, 
Timmerman R. Stereotactic body radiation therapy for early-stag e non-small-cell lung carcinoma: 
Four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys. 2009 Nov 1; 75(3): 
677-682.  
21. Grills IS, Mangona VS, Welsh R, Chmielewski G, McInerney E,  Martin S, Wloch J, Ye H, 
Kestin LL. Outcomes after stereotactic lung radiotherapy or wed ge resection for stage I non-small-
cell lung cancer. J Clin Oncol. 2010 Feb 20; 28(6): 928-935.  
SBRT and Nelfinavir 
Protocol Chair:  Phuoc Tran, MD  
J12137 (NA_00069585) - May 19, 2020 
 
 
35 
 22. Wulf J, Haedinger U, Oppitz U, Thiele W, Mueller G, Flentje  M. Stereotactic radiotherapy for 
primary lung cancer and pulmonary metastases: A noninvasive tre atment approach in medically 
inoperable patients. Int J Radiat Oncol Biol Phys. 2004 Sep 1; 60(1): 186-196.  
23. Hof H, Hoess A, Oetzel D, De bus J, Herfarth K. Stereotactic  single-dose radiotherapy of lung 
metastases. Strahlenther Onkol. 2007 Dec; 183(12): 673-678.  
24. Kim TH, Kim DY, Park JW, Kim YI, Kim SH, Park HS, Lee WJ, P ark SJ, Hong EK, Kim 
CM. Three-dimensional conformal radiotherapy of unresectable he patocellular carcinoma patients 
for whom transcatheter arterial chemoembolization was ineffecti ve or unsuitable. Am J Clin Oncol. 
2006 Dec; 29(6): 568-575.  
25. Zhou ZH, Liu LM, Chen WW, Men ZQ, Lin JH, Chen Z, Zhang XJ,  Jiang GL. Combined 
therapy of transcatheter arterial  chemoembolisation and three-d imensional conformal radiotherapy 
for hepatocellular carcinoma. Br J Radiol. 2007 Mar; 80(951): 194-201.  
26. Seo DD, Lee HC, Jang MK, Min HJ, Kim KM, Lim YS, Chung YH, Lee YS, Suh DJ, Ko GY, 
Lee YJ, Lee SG. Preoperative portal vein embolization and surgi cal resection in patients with 
hepatocellular carcinoma and sma ll future liver remnant volume:  Comparison with transarterial 
chemoembolization. Ann Surg Oncol. 2007 Dec; 14(12): 3501-3509.  
27. Kamel IR, Liapi E, Reyes DK, Zahurak M, Bluemke DA, Geschwi nd JF. Unresectable 
hepatocellular carcinoma: Serial early vascular and cellular ch anges after transarterial 
chemoembolization as detected with MR imaging. Radiology. 2009 Feb; 250(2): 466-473.  
28. Lo SS, Teh BS, Mayr NA, Olencki TE, Wang JZ, Grecula JC, Lu  J J ,  T i m m e r m a n  R D .  
Stereotactic body radiation the rapy for oligometastases. Discov Med. 2010 Sep; 10(52): 247-254.  
29. Ben-Josef E, Lawrence TS. Using a bigger hammer: The role o f stereotactic bod y radiotherapy 
in the management of oligometastases. J Clin Oncol. 2009 Apr 1; 27(10): 1537-1539.  
30. Christodouleas JP, Marks LB. Analysis of patients with olig ometastases undergoing two or 
more curative-intent stereotactic  radiotherapy courses: In rega rd to milano et al. (int J radiat oncol 
biol phys 2009;73:832-837). Int J Radiat Oncol Biol Phys. 2009 Aug 1; 74(5): 1628; author reply 
1628-9.  
31. Kavanagh BD, McGarry RC, Timme rman RD. Extracranial radiosu rgery (stereotactic body 
radiation therapy) for oligometastases. Semin Radiat Oncol. 2006 Apr; 16(2): 77-84.  
32. Niibe Y, Hayakawa K. Oligomet astases and oligo-recurrence: The new era of cancer therapy. 
Jpn J Clin Oncol. 2010 Feb; 40(2): 107-111. PMCID: PMC2813545.  
33. Cheng JC, Liu HS, Wu JK, Chung HW, Jan GJ. Inclusion of bio logical factors in parallel-
architecture normal-tissue comp lication probability model for r adiation-induced liver disease. Int 
J Radiat Oncol Biol Phys. 2005 Jul 15; 62(4): 1150-1156.  
SBRT and Nelfinavir 
Protocol Chair:  Phuoc Tran, MD  
J12137 (NA_00069585) - May 19, 2020 
 
 
36 
 34. Dawson LA, Ten Haken RK. Partial volume tolerance of the li ver to radiation. Semin Radiat 
Oncol. 2005 Oct; 15(4): 279-283.  
35. Dawson LA, Normolle D, Balter JM, McGinn CJ, Lawrence TS, T en Haken RK. Analysis of 
radiation-induced liver disease using the lyman NTCP model. Int J Radiat Oncol Biol Phys. 2002 
Jul 15; 53(4): 810-821.  
36. Reed GB,Jr, Cox AJ,Jr. The human liver after radiation inju ry. A form of veno-occlusive 
disease. Am J Pathol. 1966 Apr; 48(4): 597- 611. PMCID: PMC1916442.  
37. See AP, Zeng J, Tran PT, Lim M. Acute toxicity of second ge neration HIV protease-inhibitors 
in combination with radiotherapy:  a retrospective case series.  Radiat. Oncol. 2011 Mar 17;6:25. 
38. Plastaras JP, Vapiwala N, Ahm ed MS, Gudonis D, Cerniglia GJ , Feldman MD, Frank I, 
Gupta AK.  Validation and toxicit y of PI3K/Akt pathway inhibiti on by HIV protease inhibtors in 
humans. Cancer Biol. Ther.  2008 May;7(5):628-35. Epub 2008 May 14. 
 
SBRT and Nelfinavir 
Protocol Chair:  Phuoc Tran, MD  
J12137 (NA_00069585) - May 19, 2020 
 
 
37 
 APPENDIX I: Brief Pain Inventory Form 
 

SBRT and Nelfinavir 
Protocol Chair:  Phuoc Tran, MD  
J12137 (NA_00069585) - May 19, 2020 
 
 
38 
  

SBRT and Nelfinavir 
Protocol Chair:  Phuoc Tran, MD  
J12137 (NA_00069585) - May 19, 2020 
 
 
39 
 APPENDIX II: SKCCC DSMP 
 
           
 
                                
SBRT and Nelfinavir 
Protocol Chair:  Phuoc Tran, MD  
J12137 (NA_00069585) - May 19, 2020 
 
 
40 
 APPENDIX III:  Performance Status Criteria 
 
 
      
ECOG Performance Status Scale 
  
Karnofsky Performance Scale 
Grade Descriptions Percent Description 
0 Normal activity.  Fully active, able 
to carry on all pre-disease performance without restriction. 100 Normal, no complaints, no evidence 
of disease. 
90 Able to carry on normal activity; 
minor signs or symptoms of disease. 
1 Symptoms, but ambulatory.  
Restricted in physically strenuous activity, but ambulatory and able 
to carry out work of a light or 
sedentary nature (e.g., light housework, office work). 80 Normal activity with effort; some 
signs or symptoms of disease. 
70 Cares for self, unable to carry on 
normal activity or to do active work. 
2 In bed <50% of the time.  
Ambulatory and capable of all self-care, but unable to carry out any work activities.  Up and about more than 50% of waking hours. 60 Requires occasional assistance, but 
is able to care for most of his/her needs. 
50 Requires considerable assistance and 
frequent medical care. 
3 In bed >50% of the time.  Capable 
of only limited self-care, confined to bed or chair more than 50% of waking hours. 40 Disabled, requires special care and 
assistance. 
30 Severely disabled, hospitalization 
indicated.  Death not imminent. 
4 100% bedridden.  Completely 
disabled.  Cannot carry on any self-care.  Totally confined to bed or chair. 20 Very sick, hospita lization indicated. 
Death not imminent. 
10 Moribund, fatal processes 
progressing rapidly. 
5 Dead. 0 Dead. 